Evolution of monoclonal gammopathy of undetermined significance in patients treated with JAK inhibitors for rheumatic diseases: data from the MAJIK-SFR registry.
Fiche publication
Date publication
août 2023
Journal
Rheumatology (Oxford, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr TOUSSIROT Eric
Tous les auteurs :
Faganello D, Bertrand A, Meunier P, Avouac J, Toussirot E, Coury F, Seror R, Le Mélédo G, Germain V, Dellal A, Shima D, Hulin C, Prati C, Schaeverbeke T, Richez C, Truchetet ME, Kostine M
Lien Pubmed
Résumé
Monoclonal Gammopathy of Undetermined Significance (MGUS) is common but there are scarce data regarding the effect of disease-modifying antirheumatic drugs (DMARDs) on this pre-malignant condition. We aimed to evaluate the impact of JAK inhibitors (JAKi) on MGUS when initiated for an active rheumatic disease.
Mots clés
JAK inhibitors, Monoclonal Gammopathy of Undetermined Significance, myeloma, rheumatic diseases, rheumatoid arthritis
Référence
Rheumatology (Oxford). 2023 08 4;: